Attached files

file filename
10-K - FORM 10-K - POINT Biopharma Global Inc.tm217248d1_10k.htm
EX-4.2 - EXHIBIT 4.2 - POINT Biopharma Global Inc.tm217248d1_ex4-2.htm
EX-32.2 - EXHIBIT 32.2 - POINT Biopharma Global Inc.tm217248d1_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - POINT Biopharma Global Inc.tm217248d1_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - POINT Biopharma Global Inc.tm217248d1_ex31-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter Kolchinsky, Chief Executive Officer of Therapeutics Acquisition Corp. (the “Company”), hereby certify, that, to my knowledge:

 

(1) the Annual Report on Form 10-K for the year ended December 31, 2020 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 4, 2021

 

  /s/ Peter Kolchinsky
  Name: Peter Kolchinsky
  Title: Chief Executive Officer